| Cat. No. |
Product Name |
Information |
| PC-38035 |
CNX2006
EGFR inhibitor
|
CNX2006 (CNX-2006) is a potent, covalent, mutant-selective EGFR inhibitor with IC50 of <20 nM, weak inhibition at wild-type EGFR. |
| PC-38032 |
TQB3804
EGFR C797S inhibitor
|
TQB3804 (EGFR-IN-7) is a selective, potent, 3rd generation EGFR C797S inhibitor with IC50 of 1.07 nM and 0.13 nM for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) respectively. |
| PC-38023 |
Tucatinib
ErbB-2 (HER2) inhibitor
|
Tucatinib (Irbinitinib, ONT-380, ARRY-380) is a potent, selective, reversible and ATP-competitive inhibitor of ErbB-2 (HER2) with IC50s of 8 nM and 7 nM for ErbB-2 and p95 HER2, respectively. |
| PC-36109 |
TAS0728
|
TAS0728 (TAS-0728, TAS 0728) is a potent, selective, covalent, orally available inhibitor of HER2 kinase with IC50 of 36 nM in in vitro kinase assays. |
| PC-35826 |
JND3229
EGFR C797S inhibitor
|
JND3229 (JND-3229) is a novel highly potent, reversible EGFR C797S mutant inhibitor, potently inhibits the kinase activities of EGFRL858R/T790M and EGFRL858R/T790M/C797 with IC50 of 5.8 nM and 30.5 nM, respectively. |
| PC-35641 |
Alflutinib methanesulfonate
|
Alflutinib methanesulfonate (AST-2818) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation. |
| PC-35640 |
Alflutinib
|
Alflutinib (Furmonertinib, AST-2818) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation.. |
| PC-63499 |
TAS6417
|
Zipalertinib (TAS6417, CLN-081) is a novel potent, selective inhibitor of EGFR exon 20 insertion mutations with IC50 of 1.1-8.0 nM, >100-fold selectivity over WT EGFR. |
| PC-43452 |
Dacomitinib
EGFR inhibitor
|
Dacomitinib (PF-00299804, PF-299804) is a potent, irreversible, orally active pan-ErbB receptor tyrosine kinase inhibitor with IC50 of 6, 45.7 and 73.7 for EGFR, ERBB2 and ERBB4, respectively. |
| PC-43436 |
OSI-420
|
OSI-420 (Desmethyl Erlotinib, CP-473420) is an active metabolite of erlotinib, which is a potent EGFR tyrosin kinase inhibitor for treatment of NSCLC.. |
| PC-43354 |
Sapitinib
EGFR inhibitor
|
Sapitinib (AZD-8931, AZD8931) is a equipotent, reversible inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4. 3 and 4 nM (phosphorylation inhibition), respectively. |
| PC-42828 |
PD153035 hydrochloride
|
PD153035 (ZM 252868, AG 1517, Tyrphostin AG 1517, SU 5271) is a highly potent, specific, ATP-competitive EGFR inhibitor with IC50 of 0.025 nM. |
